Emily Chin

2.4k total citations
16 papers, 724 citations indexed

About

Emily Chin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Infectious Diseases. According to data from OpenAlex, Emily Chin has authored 16 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 3 papers in Infectious Diseases. Recurrent topics in Emily Chin's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (5 papers) and Cancer Genomics and Diagnostics (3 papers). Emily Chin is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (5 papers) and Cancer Genomics and Diagnostics (3 papers). Emily Chin collaborates with scholars based in United States, Japan and Brazil. Emily Chin's co-authors include Alice T. Shaw, Justin F. Gainor, W. Marston Linehan, Ibiayi Dagogo‐Jack, Beow Y. Yeap, Marguerite Rooney, Jochen K. Lennerz, Lorin A. Ferris, Rebecca J. Nagy and Jennifer Ackil and has published in prestigious journals such as PLoS ONE, Journal of Virology and Clinical Cancer Research.

In The Last Decade

Emily Chin

15 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emily Chin United States	12	499	354	227	214	87	16	724
Adrien Saliou France	11	177 0.4×	215 0.6×	227 1.0×	382 1.8×	146 1.7×	20	647
Gisela Sitbon Sweden	4	99 0.2×	119 0.3×	238 1.0×	185 0.9×	114 1.3×	5	535
Heather Sheppard United States	13	143 0.3×	201 0.6×	502 2.2×	319 1.5×	140 1.6×	30	825
Kate Poropatich United States	12	156 0.3×	156 0.4×	125 0.6×	47 0.2×	123 1.4×	17	601
David R. Hout United States	16	97 0.2×	168 0.5×	217 1.0×	112 0.5×	310 3.6×	32	622
Cecilia Rietz United States	9	80 0.2×	694 2.0×	178 0.8×	51 0.2×	44 0.5×	13	973
Jianping Yang New Zealand	20	110 0.2×	403 1.1×	256 1.1×	50 0.2×	32 0.4×	44	1.1k
Christopher Di Simone United States	7	107 0.2×	274 0.8×	114 0.5×	74 0.3×	10 0.1×	10	591
Marie-Ming Aynaud France	9	53 0.1×	134 0.4×	467 2.1×	149 0.7×	127 1.5×	9	717
Martin Krüger Germany	12	257 0.5×	193 0.5×	301 1.3×	63 0.3×	12 0.1×	13	890

Countries citing papers authored by Emily Chin

Since Specialization

Citations

This map shows the geographic impact of Emily Chin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Chin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Chin more than expected).

Fields of papers citing papers by Emily Chin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Chin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Chin. The network helps show where Emily Chin may publish in the future.

Co-authorship network of co-authors of Emily Chin

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Chin. A scholar is included among the top collaborators of Emily Chin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Chin. Emily Chin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Chin, Emily, et al.. (2023). Changes in postpartum contraception utilization rates during the early stage of the COVID-19 pandemic. Women s Health. 19. 902585999–902585999. 2 indexed citations

Pantel, Klaus, Claus L. Andersen, Ed Schuuring, et al.. (2023). 237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes. Annals of Oncology. 34. S276–S277. 5 indexed citations

Pentecost, Brian T., et al.. (2021). Humoral and Cell-Mediated Immune Response in Colostrum from Women Diagnosed Positive for SARS-CoV-2. Breastfeeding Medicine. 16(12). 987–994. 12 indexed citations

Digumarthy, Subba R., Dexter P. Mendoza, W. Marston Linehan, et al.. (2020). Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements. Cancers. 12(3). 693–693. 19 indexed citations

Dagogo‐Jack, Ibiayi, Marguerite Rooney, W. Marston Linehan, et al.. (2019). Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clinical Cancer Research. 25(22). 6662–6670. 112 indexed citations

Linehan, W. Marston, Adam J. Schoenfeld, Viola W. Zhu, et al.. (2019). Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. Journal of Thoracic Oncology. 15(2). 258–265. 54 indexed citations

Digumarthy, Subba R., Dexter P. Mendoza, W. Marston Linehan, et al.. (2019). Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non–Small-cell Lung Cancer. Clinical Lung Cancer. 21(2). 153–159.e3. 25 indexed citations

Dagogo‐Jack, Ibiayi, Marguerite Rooney, Rebecca J. Nagy, et al.. (2019). Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. Journal of Thoracic Oncology. 14(5). 816–824. 75 indexed citations

Linehan, W. Marston, Emily Chin, Beow Y. Yeap, et al.. (2018). Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 135–140. 92 indexed citations

10.

Chaft, Jamie E., Ibiayi Dagogo‐Jack, Fernando C. Santini, et al.. (2018). Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer. 122. 67–71. 35 indexed citations

11.

Gainor, Justin F., Leila Dardaei, Satoshi Yoda, et al.. (2016). Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. European Journal of Cancer. 69. S138–S138. 119 indexed citations

12.

Otto‐Duessel, Maya, Miaoling He, Leila Su, et al.. (2013). Ligand-Independent and Tissue-Selective Androgen Receptor Inhibition by Pyrvinium. ACS Chemical Biology. 9(3). 692–702. 46 indexed citations

13.

Dudley, Dawn M., Emily Chin, Benjamin N. Bimber, et al.. (2012). Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for Surveillance of HIV Drug Resistance. PLoS ONE. 7(5). e36494–e36494. 70 indexed citations

14.

Bimber, Benjamin N., Dawn M. Dudley, Michael Lauck, et al.. (2010). Whole-Genome Characterization of Human and Simian Immunodeficiency Virus Intrahost Diversity by Ultradeep Pyrosequencing. Journal of Virology. 84(22). 12087–12092. 51 indexed citations

15.

Sagawa, Motoyasu, Yuichi Saito, Masaaki Sato, et al.. (1995). [Detection of human papillomavirus type 16, 18 and 33 DNA in stage I (pT1N0M0) squamous cell carcinoma of the lung by polymerase chain reaction].. PubMed. 48(5). 360–2. 7 indexed citations

16.

Satoh, Makoto, et al.. (1994). [A case of lung cancer with axillary nodal involvement].. PubMed. 47(6). 489–91.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact